590 related articles for article (PubMed ID: 20637965)
1. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
[TBL] [Abstract][Full Text] [Related]
3. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
4. Primary prevention of osteoporosis: mass screening scenario or prescreening with questionnaires? An economic perspective.
Richy F; Ethgen O; Bruyere O; Mawet A; Reginster JY
J Bone Miner Res; 2004 Dec; 19(12):1955-60. PubMed ID: 15537437
[TBL] [Abstract][Full Text] [Related]
5. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.
Hoerger TJ; Wittenborn JS; Segel JE; Burrows NR; Imai K; Eggers P; Pavkov ME; Jordan R; Hailpern SM; Schoolwerth AC; Williams DE;
Am J Kidney Dis; 2010 Mar; 55(3):463-73. PubMed ID: 20116910
[TBL] [Abstract][Full Text] [Related]
6. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
Atthobari J; Brantsma AH; Gansevoort RT; Visser ST; Asselbergs FW; van Gilst WH; de Jong PE; de Jong-van den Berg LT;
Nephrol Dial Transplant; 2006 Nov; 21(11):3106-14. PubMed ID: 16720593
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease.
Akker-van Marle ME; Rijnders ME; Dommelen P; Fekkes M; Wouwe JP; Amelink-Verburg MP; Verkerk PH
BJOG; 2005 Jun; 112(6):820-6. PubMed ID: 15924544
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.
Boersma C; Voors AA; Visser ST; de Jong-van den Berg LT; Postma MJ
Am J Cardiovasc Drugs; 2010; 10(1):49-54. PubMed ID: 20104934
[TBL] [Abstract][Full Text] [Related]
11. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
Ess SM; Szucs TD
Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
[TBL] [Abstract][Full Text] [Related]
12. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
14. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening.
Halbesma N; Kuiken DS; Brantsma AH; Bakker SJ; Wetzels JF; De Zeeuw D; De Jong PE; Gansevoort RT
J Am Soc Nephrol; 2006 Sep; 17(9):2582-90. PubMed ID: 16899519
[TBL] [Abstract][Full Text] [Related]
15. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
16. What predicts progression and regression of urinary albumin excretion in the nondiabetic population?
Brantsma AH; Atthobari J; Bakker SJ; de Zeeuw D; de Jong PE; Gansevoort RT
J Am Soc Nephrol; 2007 Feb; 18(2):637-45. PubMed ID: 17215442
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
Brantsma AH; Bakker SJ; Hillege HL; de Zeeuw D; de Jong PE; Gansevoort RT;
Nephrol Dial Transplant; 2008 Dec; 23(12):3851-8. PubMed ID: 18641082
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
Anderson R; Haas M; Shanahan M
Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
[TBL] [Abstract][Full Text] [Related]
19. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
Kwon JS; Lu KH
Obstet Gynecol; 2008 Jul; 112(1):56-63. PubMed ID: 18591308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
